Lupin gets USFDA nod for generic hypertension drug
Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited, announced the launch of Propranolol LA (long-acting) capsules, 60 mg, 80 mg, 120 mg and 160 mg, in Canada. Propranolol LA is a generic equivalent of Inderal LA, it provides an effective treatment solution since the discontinuation of Inderal® LA for patients and healthcare practitioners. Propranolol LA's launch caters to the needs of Canadian patients, reaffirming Lupin's commitment to enhancing healthcare access and affordability.
MONTREAL, Aug. 29, 2023 /PRNewswire/ -- Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited (Lupin), today announced the launch of Propranolol LA (long-acting) capsules,60 mg, 80 mg, 120 mg and 160 mg, in Canada. Propranolol LA is a generic equivalent of Inderal® LA, it provides an effective treatment solution since the discontinuation of Inderal® LA for patients and healthcare practitioners. Propranolol LA's launch caters to the needs of Canadian patients,reaffirming Lupin's commitment to enhancing healthcare access and affordability.
FDA Confirms Paragraph IV Patent Litigation for Hemangeol (Propranolol Hydrochloride Solution)
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and six months ended June 30, 2022.
AstraZeneca hawks suite of hypertension drugs for $350M in latest asset sale
The NHS’ Healthcare Safety Investigation Branch (HSIB) has unveiled new concerns about the toxicity of a commonly prescribed beta blocker, propranolol.
On the same day that it’s getting back an experimental IL-23 drug from AbbVie and Allergan’s pre-merger divestiture exercise, AstraZeneca has engineered a sale of its own.
AMTA's Generic Propranolol Hydrochloride Receives Approval In US
Pharma major Lupin Limited announced that it has received approval for its propranolol hydrochloride extended-release (ER) capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada.